Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka, significantly increasing its addressable market to an estimated $13.0 billion. The expansion supports planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, subject to regulatory approvals, as the company builds regional distribution channels and positions for broader deployment of its molecular diagnostics solutions.
The agreement marks a strategic move for Co-Diagnostics, which has been focusing on expanding its footprint in emerging markets. By adding these four countries to its distribution network, CoSara now covers a vast region with high demand for affordable and accurate diagnostic tools. The $13 billion addressable market estimate underscores the potential for growth, particularly in areas where infectious diseases remain a significant public health challenge.
Co-Diagnostics’ proprietary technology, which utilizes nucleic acid detection, forms the basis of its product offerings. The CoSara PCR Pro platform, designed for point-of-care use, aims to bring laboratory-quality testing to remote and resource-limited settings. The SARAGENE product line complements this by offering a range of molecular diagnostics for various diseases. Both platforms are subject to regulatory approvals in the newly added territories, which will be a key milestone for commercialization.
“This expansion into Bangladesh, Pakistan, Nepal, and Sri Lanka represents a significant step forward in our mission to make molecular diagnostics accessible worldwide,” said a company spokesperson. “The regulatory processes in these countries are underway, and we are optimistic about the potential to improve healthcare outcomes through our innovative solutions.”
The announcement builds on Co-Diagnostics’ earlier efforts to establish a foothold in India through its joint venture. CoSara has been instrumental in navigating local regulations and building distribution networks. The expanded territory now includes some of the most populous nations in South Asia, where healthcare infrastructure varies widely, and the need for reliable diagnostics is acute.
For more information about the full press release, visit https://ibn.fm/2aATV. Additional details about the company and its technologies can be found on the Co-Diagnostics website at https://co-dx.com/.
Forward-looking statements in this release involve risks and uncertainties, including regulatory approvals and market acceptance, which could cause actual results to differ materially. These are detailed in the company’s filings with the SEC, including its most recent Annual Report on Form 10-K. The company undertakes no duty to update these statements unless required by law.
